These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24258455)

  • 1. Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report.
    Krens LL; Baas JM; de Jong FA; Guchelaar HJ; Gelderblom H
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):429-33. PubMed ID: 24258455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
    Saif MW; Kaley K; Chu E; Copur MS
    Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer.
    Liao MZ; Prenen H; Dutta S; Upreti VV
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):665-672. PubMed ID: 34213592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on panitumumab in metastatic colorectal cancer.
    Keating GM
    BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma.
    Peeters M; Cohn A; Köhne CH; Douillard JY
    Clin Colorectal Cancer; 2012 Mar; 11(1):14-23. PubMed ID: 21925954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
    Hecht JR; Patnaik A; Berlin J; Venook A; Malik I; Tchekmedyian S; Navale L; Amado RG; Meropol NJ
    Cancer; 2007 Sep; 110(5):980-8. PubMed ID: 17671985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials.
    Koukakis R; Gatta F; Hechmati G; Siena S
    Qual Life Res; 2016 Oct; 25(10):2645-2656. PubMed ID: 27083443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective panitumumab treatment in patients with heavily pre-treated metastatic colorectal cancer: a case series.
    Tzovaras AA; Karagiannis A; Margari C; Barla G; Ardavanis A
    Anticancer Res; 2011 Mar; 31(3):1033-7. PubMed ID: 21498734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panitumumab monotherapy as a second-line treatment in metastasised colorectal cancer: a single centre experience.
    van Hellemond IE; Creemers GJ; van Warmerdam LJ; de Jong FA; Koornstra RH
    Clin Oncol (R Coll Radiol); 2014 Mar; 26(3):135-41. PubMed ID: 24246276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of panitumumab into the treatment of colorectal cancer.
    Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
    Saif MW; Peccerillo J; Potter V
    Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panitumumab safety for treating colorectal cancer.
    Stremitzer S; Sebio A; Stintzing S; Lenz HJ
    Expert Opin Drug Saf; 2014 Jun; 13(6):843-51. PubMed ID: 24766434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
    Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
    Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Panitumumab-treatment of metastatic colorectal cancer].
    Pikó B
    Magy Onkol; 2009 Jun; 53(2):135-42. PubMed ID: 19581179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Panitumumab].
    Musch A
    Med Monatsschr Pharm; 2008 Apr; 31(4):122-6. PubMed ID: 18497243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of panitumumab for K-ras wild-type unresectable or recurrent colorectal cancer - a study focusing on first-line treatment].
    Mitomo S; Suto T; Umemura A; Ishida K; Kanno K; Takeda D; Fujita T; Otsuka K; Nitta H; Uesugi N; Sugai T; Wakabayashi G
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):731-5. PubMed ID: 25129084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.